# Diana Peng Bockus

> Diana Peng Bockus is the Chief Executive Officer of NGM Biopharmaceuticals, a South San Francisco biotech developing first-in-class medicines for liver disease, oncology, and ophthalmology. Appointed CEO in April 2025, she joined the company in 2020 to lead business development and restructured a pivotal Merck partnership that freed NGM to build a wholly owned pipeline. A Stanford and Wharton graduate with roots in management consulting at Bain & Company, she now steers a privately held biotech backed by $515M in total funding, focused on rare diseases like primary sclerosing cholangitis and hyperemesis gravidarum.

- **Role:** Chief Executive Officer at NGM Biopharmaceuticals
- **Organizations:** NGM Biopharmaceuticals, RefleXion Medical, Bain & Company, Wharton Healthcare Management Alumni Association
- **Nationality:** American
- **Education:** Master of Business Administration (MBA), The Wharton School, University of Pennsylvania, Bachelor's degrees in Human Biology and Sociology, Stanford University
- **Known for:** Appointed CEO of NGM Biopharmaceuticals in April 2025, Restructured NGM's partnership with Merck, enabling NGM to reclaim its wholly owned pipeline across metabolic disease, ophthalmology, and oncology, Supported the $122M Series A financing led by The Column Group in July 2024

## Career timeline

- **2005-2009** — Attended Stanford University, earning degrees in Human Biology and Sociology
- **2012-2014** — Earned MBA from The Wharton School, University of Pennsylvania; served on Executive Board of Wharton Healthcare Management Alumni Association
- **Pre-2020** — Worked as management consultant at Bain & Company, specializing in biotech and pharmaceutical companies
- **Pre-2020** — Served as Senior Director, Strategy and Business Development at RefleXion Medical, focusing on pharmaceutical and radiopharmaceutical partnerships
- **2020-11** — Joined NGM Biopharmaceuticals as Vice President of Corporate Development and Business Development lead
- **2021** — Restructured the Merck partnership, returning full control of NGM's portfolio to the company
- **2021-2024** — Expanded role at NGM to include corporate and product strategy
- **2024-04** — Supported take-private merger with The Column Group at $1.55/share
- **2024-07** — NGM Bio raised $122M Series A led by The Column Group to fund aldafermin PSC trial and NGM120 HG trial
- **2025-04** — Appointed Chief Executive Officer of NGM Biopharmaceuticals
- **2025-02** — First patient dosed in EMERALD Phase 2 trial of NGM120 for hyperemesis gravidarum

## Achievements

- Appointed CEO of NGM Biopharmaceuticals in April 2025
- Restructured NGM's partnership with Merck, enabling NGM to reclaim its wholly owned pipeline across metabolic disease, ophthalmology, and oncology
- Supported the $122M Series A financing led by The Column Group in July 2024
- Led the strategic repositioning of NGM Bio following its take-private acquisition by The Column Group in April 2024
- Served on the Executive Board of the Wharton Healthcare Management Alumni Association
- Oversaw initiation of the EMERALD Phase 2 clinical trial of NGM120 for hyperemesis gravidarum (first patient dosed February 2025)

## Latest updates

- **2025-04** — Appointed Chief Executive Officer of NGM Biopharmaceuticals
- **2025-02** — NGM Bio dosed first participant in EMERALD Phase 2 trial of NGM120 for hyperemesis gravidarum
- **2025-02** — NGM Bio appointed Wendy Yeh, M.D. as Chief Medical Officer
- **2024-07** — NGM Bio raised $122M Series A financing led by The Column Group
- **2024-04** — NGM Bio completed take-private merger with The Column Group at $1.55/share

## Links

- Website: https://ngmbio.com
- LinkedIn: http://www.linkedin.com/in/dianapbockus

---

Profile page: https://yespress.io/diana-peng
Published by YesPress — https://yespress.io
Last updated: 2026-05-13